ClinicalTrials.gg
RecruitingNCT04866329FERTENOXUpdated Jul 25, 2024

Female Fertility, Environmental Agents and Stress Oxidant

An observational study in Female Infertility, sponsored by University Hospital, Tours. Recruiting at 1 site in France. Open to female participants aged 18 Years to 43 Years. Per ClinicalTrials.gov, last updated 2024-07-25.

Sponsored by University Hospital, Tours · Observational

How we know

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 43 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Infertility, Female with a site in France — 5 open to participants now, 5 under way, 1 of them phase 3. Infertility, Female · France.

Planned enrollment
5th of 11
500 · median 127
Started
2021
with 2 others
Observational
11 of 20
3 open now
Registered
10th of 20
by date

Among the 20 studies in Infertility, Female with a site in France, this one is the 5th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2021, is one of 11 observational ones, and was the 10th registered.

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

5 of the 20 studies in Infertility, Female with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 43 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Infertility, Female with a site in France, or all of them as a file.
02

Study summary

Synthetic products used in industrial, pharmaceutical, agro-alimentary or agricultural fields are found in our environment. Thus, humans could be simultaneously exposed to several of these pollutants. Furthermore, these environmental agents exert or could exert adverse actions on fertility, by altering gamete and embryo quality through endocrine disruptor effects or through increase in oxidative stress in gonads (cellular pathway known to be involved in several human reproductive pathologies).

In this context, the objectives of the present project are to obtain descriptive and analytical data on woman and oocyte exposure to several environmental agents (bisphenols, ethynylestradiol and glyphosate). The relation between these pollutant measures in follicular fluid and urine (from women receiving follow-up of in vitro fertilization (IVF) protocol in the University hospital of Tours, France) and the oocyte quality, the IVF and pregnancy successes will be studied. Several oxidative stress biomarkers in blood and follicular fluid will be also measured for these women, who will complete a questionnaire on their lifestyles. Finally, thanks to in vitro approaches, the effects and the mechanisms of action (including oxidative stress) of these pollutants (alone or in cocktails) will be studied on granulosa cells from these patients.

Read the detailed description

After being informed about the project Fertenox during a meeting describing about the Fecondation In Vitro protocol, all women patients not opposing to participate in the study and to use individual information will be included in the research during the usual bacteriological exam performed 1-2 months before oocyte pick up in the University hospital. They will receive the questionnaire on their lifestyle during this exam.

On the eve of the oocyte pick up (at the end of ovarian stimulation) during the usual blood collection, three additional tubes of blood will be collected for each patient in the University hospital. Women will also receive the screw-top container for morning-after urine sample and the completion of the lifestyle questionnaire will be checked (some advices will be done if necessary to help patients to fill out the questionnaire). Samples will be treated, aliquoted and stored according to requirements the same day.

The day of the oocyte pick up, the first morning urine will be collected by patients at home (or otherwise in the hospital). The completed questionnaire will be recovered and follicular fluid and granulosa cells will be collected for each woman. Samples will be aliquoted and stored according to requirements the same day. Granulosa cells will be cultured for in vitro approaches in research labs the same day.

Tubes of blood, urine and follicular fluid will be coded and kept at -80°C in the University hospital until their shipment to laboratories, where analyses of pollutants (bisphenols, ethynylestradiol and glyphosate) and analyses of oxidative stress biomarkers (antioxidant vitamins, FRAP), activity of several enzymes (catalase, superoxide dismutase, glutathione peroxidase) and oxidized lipids) will be performed.

03

Conditions studied

  • Female Infertility

Browse trials for

Keywords

  • Environmental pollutants
  • Bisphenols
  • Ethynylestradiol
  • Glyphosate
  • Oxidative stress
  • Oocyte and embryo quality
  • In vitro fertilization
  • Pregnancy
  • Follicular fluid and urine biomarkers
04

Who can participate

Ages eligible
18 Years to 43 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women followed in the department for an in vitro fertilisation procedure

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Woman aged 18 to 43 years old
  • First oocyte puncture (IVF rank = 1)

Exclusion criteria

Exclusion Criteria:

  • Opposition to data processing
  • IVF rank equal or greater than 2
  • Egg donation
  • Intracytoplasmic Sperm Injection with testicular
  • Intracytoplasmic Sperm Injection with self-preservation straw
  • Sperm donation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • In Vitro Fertilisation protocol

    Women followed in the department for an in vitro fertilisation protocol

    Other: Blood sample · Other: Urine sample · Other: Follicular fluid and granulosa cells sample

Interventions

  • OtherBlood sample

    Additional blood sampling at the end of ovarian stimulation monitoring (the eve of the oocyte pick-up)

  • OtherUrine sample

    Collection of the first urine in the morning on the day of the oocyte pick-up

  • OtherFollicular fluid and granulosa cells sample

    Collection of follicular fluid and granulosa cells during oocyte pick-up.

06

What researchers measure

Primary outcomes

  1. Presence or absence of ethinylestradiol in follicular fluid

    Assessed by measure of ethinylestradiol in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)

    Time frame: Baseline

  2. Presence or absence of ethinylestradiol in urine

    Assessed by measure of ethinylestradiol in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)

    Time frame: Baseline

  3. Presence or absence of bisphenols in follicular fluid

    Assessed by measure of bisphenols in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)

    Time frame: Baseline

  4. Presence or absence of bisphenols in urine

    Assessed by measure of bisphenols in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)

    Time frame: Baseline

  5. Presence or absence of glyphosate in follicular fluid

    Assessed by measure of glyphosate in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)

    Time frame: baseline

  6. Presence or absence of glyphosate in urine

    Assessed by measure of glyphosate in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)

    Time frame: baseline

  7. Concentration of ethinylestradiol in follicular fluid

    Assessed by concentration of ethinylestradiol in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)

    Time frame: baseline

  8. Concentration of ethinylestradiol in urine

    Assessed by concentration of ethinylestradiol in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)

    Time frame: baseline

  9. Concentration of bisphenols in follicular fluid

    Assessed by concentration of bisphenols in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)

    Time frame: baseline

  10. Concentration of bisphenols in urine

    Assessed by concentration of bisphenols in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)

    Time frame: baseline

  11. Concentration of glyphosate in follicular fluid

    Assessed by concentration of glyphosate in follicular fluid by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)

    Time frame: baseline

  12. Concentration of glyphosate in urine

    Assessed by concentration of glyphosate in urine by Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)

    Time frame: baseline

Secondary outcomes

  1. Oocyte quality

    Assessed by nuclear maturity of each collected punctured oocyte

    Time frame: baseline

  2. Embryo quality

    Assessed by in vitro early embryo developmental competence of each punctured oocyte (Day 2 embryo morphology, ability to reach the blastocyst stage, Day 5/6 blastocyst morphology, blastocyst outcome (transfer, freezing, discarding)

    Time frame: Day 2 and day 5/6 after oocyte pick up

  3. Embryo implantation success (pregnancy success)

    Assessed by confirmation of a clinical pregnancy (blood beta human chorionic gonadotropin assay: \> 1000 Unity Intenational /L), by confirmation of on-going pregnancy (ultrasound measure of foetus cardiac activity) and by confirmation delivery of live and healthy birth

    Time frame: From day 7 after embryo transfer for beta hCG assay, at 8 weeks of amenorrhea for foetus cardiac activity and after birth

  4. Oxidative stress biomarkers in follicular fluid

    Assessed by measure of antioxidant vitamins (carotenoids, vitamin E, retinol) by High Performance Liquid Chromatography

    Time frame: baseline

  5. Oxidative stress biomarkers in follicular fluid

    Assessed by measure of oxidized lipids (isoprostanoids) by LC-MS/MS

    Time frame: Baseline

  6. Oxidative stress biomarkers in follicular fluid

    Assessed by measure of antioxidant power (FRAP: Ferric ion Reducing Antioxidant Power) by spectrophotometry

    Time frame: Baseline

  7. Oxidative stress biomarkers in follicular fluid

    Assessed by measure of glutathione peroxidase activity by spectrophometry

    Time frame: Baseline

  8. Oxidative stress biomarkers in blood

    Assessed by measure of plasma antioxidant vitamins (carotenoids, vitamin E, retinol) by HPLC

    Time frame: On the eve of baseline

  9. Oxidative stress biomarkers in blood

    Assessed by measure of plasma oxidized lipids (isoprostanoids) by LC-MS/M

    Time frame: On the eve of baseline

  10. Oxidative stress biomarkers in blood

    Assessed by measure of plasma antioxidant power (FRAP) by spectrophotometry

    Time frame: On the eve of baseline

  11. Oxidative stress biomarkers in blood

    Assessed by measure of activities of glutathione peroxidase, catalase and superoxide dismutase in red blood cells by UV and visible spectrophometry

    Time frame: On the eve of baseline

  12. Oxidative stress biomarkers in urine

    Assessed by measure of oxidized lipids (isoprostanoids) by LC-MS/MS

    Time frame: baseline

  13. Information on woman lifestyles

    Assessed by a questionnaire on sociodemographic characteristics, smoking, physical activity, professional and environmental expositions, consumption of dietary supplements (antioxidants), consumption of drinks (tap water, from plastic bottle, cans...), food reheating habit, consumption of food from tin box, use of hygiene and cosmetic products...

    Time frame: The 3 last months of lifestyles before baseline

  14. Pollutant effects on patient granulosa cells in vitro

    Assessed on cellular viability (CCK8, live-dead assay)

    Time frame: after 24 or 48h of exposure

  15. Pollutant effects on patient granulosa cells in vitro

    Assessed on proliferation (BrdU)

    Time frame: after 24 or 48h of exposure

  16. Pollutant effects on patient granulosa cells in vitro

    Assessed on steroid production (ELISA, LC-MS)

    Time frame: after 48 or 72h of exposure

  17. Pollutant effects on patient granulosa cells in vitro

    Assessed on energetic metabolism (mitochondrial and glycolytic activities by Seahorse and Omnilog assays)

    Time frame: after 1 or 24h of exposure

  18. Pollutant effects on patient granulosa cells in vitro

    Assessed on oxidative stress biomarkers (reactive oxygen production, Nrf2 nuclear translocation by confocal microscopy, cytometry and fluorimetry)

    Time frame: after 5, 6 or 24h of exposure

  19. Pollutant effects on patient granulosa cells in vitro

    Assessed on protein expression (Western Blotting) of several markers of the studied functions (including oxidative stress)

    Time frame: after 24, 48 or 72h of exposure

  20. Pollutant effects on patient granulosa cells in vitro

    Assessed on gene expression (RNAseq and Quantitative Reverse Transcription-PCR) of several markers of the studied functions (including oxidative stress)

    Time frame: after 6 or 24h of exposure

  21. Pollutant effects on patient granulosa cells in vitro

    Assessed on protein expression (Western Blotting ) of signaling pathways

    Time frame: after 1, 5, 10, 30 and 60 min of exposure

  22. Pollutant effects on patient granulosa cells in vitro

    Assessed on gene expression (RNAseq and qRT-PCR) of signaling pathways

    Time frame: after 6h of exposure

07

Study locations

1 of 1 sites recruiting
  • Department of Reproductive Medicine and Biology, Univesity Hospital, Tours
    Tours, 37044, France
    Recruiting
    • Fabrice GUERIF, MD-PhD · Contact
    • Claire VIGNAULT, MD · Contact
    • Fabrice GUERIF, MD-PhD · Principal investigator
    • Claire VIGNAULT, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.

Of 85 non-industry observational studies under Infertility, Female, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 69. This study's planned 60 months is above that.

Counting every sponsor, half of 88 studies reached it within 36 months; a quarter within 18 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2021
First posted
Apr 29, 2021
StartActual
Dec 8, 2021
Primary completionEst.
Dec 8, 2026
CompletionEst.
Dec 2027
Last update
Jul 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04866329
Responsible party
Sponsor
First posted
Apr 29, 2021
Start date
Dec 8, 2021
Primary completion
Dec 8, 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 25, 2024

Study contacts

Fabrice GUERIF, MD-PhD
Contact
fabrice.guerif@univ-tours.fr
02.47.47.84.76 ext. +33
Virginie MAILLARD, PhD
Contact
virginie.maillard@inrae.fr
02.47.42.79.71 ext. +33
Fabrice GUERIF, MD-PhD
principal investigator · University Hospital, Tours

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion